Postpartum Depression “Baby Blues”

 

 

Definition

 

Postpartum depression (PPD) is a complex mix of physical, emotional, and behavioral changes that happen in a woman after giving birth.

 

Postpartum depression is linked to chemical, social, and psychological changes associated with having a baby.

 

 

  Epidemiology

 

Most new mothers experience the "baby blues" after delivery. About one out of every 10 of these women will develop a more severe and longer-lasting depression after delivery. About one in 1,000 women develops a more serious condition called postpartum psychosis.

 

   

Causes and risk factors

 

No specific cause of postpartum depression has been found.

            Hormone imbalance is thought to play a role: Levels of the hormones estrogen, progesterone, and cortisol fall dramatically within 48 hours after delivery.

 

Other known risk factors are:

 

            Mental illness before pregnancy

            Mental illness, including postpartum depression, in the family

            Postpartum mental disorder after an earlier pregnancy

            Conflict in the marriage, loss of employment, or poor social support from friends and family

            Pregnancy loss such as miscarriage or stillbirth

            Age at time of pregnancy -- the younger you are, the higher the risk

            Children -- the more you have, the more likely you are to be depressed in a subsequent pregnancy

            Limited social support

            Living alone

 

 

Sign and symptoms

 

Signs and symptoms usually appear any time from 24 hours to a few months after delivery. The most common signs and symptoms are:

 

1262013146.jpg

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

            Sad mood, frequent crying

            Lack of pleasure or interest in activities that once gave pleasure

            Sleep disturbance

            Weight loss

            Loss of energy

            Agitation or anxiety

            Feelings of worthlessness or guilt

            Trouble concentrating or making decisions

            Thoughts of death, suicide or homicide of the baby

            Decreased interest in sex

            Feelings of rejection

 

 

1262013156.jpg

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

A mother with postpartum depression may also:

 

            Be unable to care for herself or her baby

            Be afraid to be alone with her baby

            Have negative feelings toward the baby or even think about harming the baby

            Worry intensely about the baby, or have little interest in the baby

 

 

 

 

  1262013159.jpg

  1262013202.jpg

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     

Prevention

 

Having good social support from family, friends, and coworkers may help reduce the seriousness of postpartum depression, but may not prevent it.

 

Women who had postpartum depression after past pregnancies may be less likely to develop postpartum depression again if they start taking antidepressant medications after they deliver.

 

 

 

Treatment

 

For postpartum blues, no specific treatment may be necessary because the condition goes away by itself and usually does not result in severe symptoms

 

Postpartum depression is treated differently depending on the type and severity of a woman's symptoms

 

Treatment options include anti-anxiety or antidepressant medications, psychotherapy, and participation in a support group for emotional support and education

 

Self care at Home

 

            Surround yourself with supportive family members and friends.

            Get as much rest as you can. Nap when the baby naps.

            Try not to spend much time alone (Spend some time alone with your husband or partner).

            Take a shower and get dressed every day.

            Get out of the house. Take a walk, see a friend, do something you enjoy.

            Don't worry too much about the housework.

            Talk to other mothers. You can learn from each other, and their experiences can be reassuring.

 

 

1262013205.jpg

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

References

 

1-Roxanne Dryden-Edwards, MD, (2013) E medicine health. Postpartum Depression.

2-WebMed, (2013). Postpartum Depression

3-Pubmed Health (2012). Postpartum Depression

4-Mayo Clinic, (2012). Postpartum Depression

 

 

 

 

 

 

 

 

 

Clinical Pharmacist

 

Clinical Pharmacist's Role in Preventing Adverse Drug Events: Brief Update Review


Peter Glassman, MBBS, MSc


Chapter 4Clinical Pharmacist's Role in Preventing Adverse Drug Events: Brief Update Review
Peter Glassman, MBBS, MSc


Introduction


In our original report, “Making Health Care Safer” 2001, Kaushal and Bates noted that over 770,000 people were harmed or died in hospitals annually from adverse drug events (ADE),1-4 with incidence rates in hospital-based studies ranging from 2 to 7 per 100 admissions

 

1,5-7 In the outpatient setting, as they also noted, one study on adults estimated the ADE incidence rate at 3 percent.8The purpose of this review is to update the data on the incidence of ADEs in hospital settings and to review measures aimed at preventing these events, including the role of the clinical pharmacist.

 

We searched the literature from 2001 to 2011 and included studies most relevant to clinical pharmacist interventions on medication errors and adverse drug events in various health care settings.

 

Our focus was on studies that to some degree addressed the possible association between clinical pharmacist activities and improved prescribing practices and/or assessed whether such activities might lead to reduced medication errors and adverse drug events


What is the Role of the Clinical Pharmacist in Preventing Adverse Drug Events


There have been various patient safety initiatives implemented that involve pharmacists with the goal of reducing ADEs.

 

These initiatives are often based on the premise that clinical pharmacists can play an important role in intercepting and acting on possible prescribing errors and/or recognizing drug-related problems before injury, or further injury, can occur. This concept has been tested in a variety of settings in a variety of ways.


In the original report, Kaushal and Bates4 noted that in a seminal study by Leape and colleagues,9 a clinical pharmacist participating in an intensive care unit team led to “a statistically significant 66% decrease in preventable ADEs due to medication ordering.”

 

Another study suggested that ward-based clinical pharmacists may benefit inpatient medication use safety and quality.

 

10 A single study in a geriatric population found a decrease in medication errors at the time of inpatient discharge when clinical pharmacists were involved.

 

11 Based on a meta-analysis, clinical pharmacists were considered to have a modest effect on maintaining acceptable drug ranges.

 

12 In the ambulatory setting, the authors noted that clinical pharmacists may have positive impacts on a variety of chronic diseases (hypertension, hypercholesterolemia, chronic heart failure, and diabetes).

 

13 However, these ambulatory studies had significant limitations and potential biases, making generalizations problematic.4
At the time of the first review,4 the authors noted that, in two studies, physicians were receptive to and often acted on clinical pharmacist interventions9,14 attesting to the often collaborative relationship between the two groups.

 

Overall, Kaushal and Bates concluded that, “Given the other well-documented benefits of clinical pharmacists and the promising results in the inpatient setting, more focused research documenting the impact of clinical pharmacist interventions on medication errors and ADEs is warranted.”

What Have We Learned About the Role of Clinical Pharmacists?


Recent Reviews and Systematic Evaluations Suggest Clinical Pharmacists Improve Medication Management


Since the 2001 report, several new systematic reviews, have addressed the role of clinical pharmacists in different clinical settings. The largest such review was Kaboli and colleagues15 (AMSTAR score 7 positive of 9 relevant domains).

 

This review included studies from 1985 to 2005 that assessed clinical pharmacists' interventions in inpatient care.

 

Eligible studies were those using concurrent controls or time series design, and measuring a number of different outcomes.


Thirty six studies contributed evidence to the review, including 10 studies of pharmacists' participation on rounds, 11 studies of their participation in medication reconciliation, and 15 studies of drug-specific services (e.g. coumadin, antibiotics).

 

The review was narrative, and concluded that the evidence “supports the use of clinical pharmacists in the inpatient setting to improve the quality, safety and efficiency of care,” although noting that the evidence base is still limited by small sample size, many studies were conducted at only a single institution, and most studies have differing measures of outcome.


Three other reviews dealt with clinical pharmacists benefit in the care of elderly adults, in nursing homes, and pediatric patients.


Hanlon and colleagues16 found a number of benefits for elderly adults, in a variety of settings, in optimizing prescribing (i.e., improving quality of pharmaceutical care) and reducing drug-related problems.

 

While there was scant evidence on reducing adverse drug events, they commented on the difficulty in designing a study that would show ADR reduction, noting that to detect a 25% decrease in adverse effects, due to a pharmacist intervention, would require randomizing at least 800 to 1400 elderly patients.

 

This review scored 4 of 9 relevant AMSTAR domains.

 

In a narrative review of interventions in nursing homes, Marcum and colleagues included five randomized controlled studies assessing the impact of clinical pharmacists on various outcomes, including drug-related adverse events; they also included two studies with a pharmacist or pharmacologist as part of a multidisciplinary approach.

 

While some studies showed significant differences in the numbers and/or choices of (or changes in) drugs, clinical outcomes--measured in various ways--were mixed, tending overall to show inconsistent and/or nominal impacts.

 

17 This review scored 6 of 9 relevant AMSTAR domains.

 

Sanghera and colleagues18 noted that pharmacists provide important improvements on drug therapy for children. Many of the 18 studies in the review were older, and methodologies differed (e.g., measuring outcomes in various ways, by various designs and definitions), but an overall positive impact was consistently seen in the studies reviewed. Most of the studies were in the inpatient setting, and only three were in the outpatient area.

 

Even so, the review highlighted that pharmacists play a crucial role in detecting and correcting medication errors, such as dosing mistakes, sometimes potentially lethal ones.

 

The authors concluded, “…pharmacists reviewing medication charts is very important in identifying medication-related problems; hence it is likely to be the most effective factor in improving drug therapy in children.” It should be kept in mind that many of the studies pre-dated the electronic era.

 

This review scored 7 of 9 relevant AMSTAR domains.


Another review, by Cohen and colleagues,19 included 16 studies of pharmacist activities in the Emergency Department (AMSTAR score 6 positive of 9 relevant domains).

 

Again noted was the wide diversity of tasks in which pharmacists were engaged, including (but not limited to) providing drug information, patient counseling, precepting, toxicology case assistance and various forms of therapeutic consultations, interventions and managements, including medication error prevention (though included studies were limited in this latter regard).


By and large, these reviews support clinical pharmacist activities in improving medication management. In general, three issues emerge from the literature.

 

First, clinical pharmacists are engaged in a multitude of patient level activities, including recognizing, intercepting, and documenting drug-related problems, as well as assisting in optimizing pharmaceutical choices for patients and, in some cases, engaging in specific interventions or in specific disease management practices.

 

Second, it is problematic to accurately capture all that pharmacists do at either an individual patient level or at an organization level,20 which makes it that much more difficult to assess their impact, especially since clinical pharmacists do not work in isolation but rather with other clinicians and, frequently, within hospitals or health care systems or settings.

 

Third, studies that attempt to show the benefit of pharmacists engaged in various activities from a larger vantage point (e.g., assessing whether adding a pharmacist to a ward team reduces medication errors or adverse drug events) often have challenges in their interpretation, including lack of concurrent control groups, indeterminate definitions of suboptimal prescribing, varying definitions of medication errors and preventable adverse drug events, different methods of error and event capture and reporting, and varying clinical outcome assessments.

 

Even so, while individual studies do not always demonstrate benefits from an organizational perspective, the body of work suggests that pharmacists provide substantial value to patient care, clinical teams, institutions, and health care organizations.


Original Studies Not Included in the Systematic Reviews Show that Interventions With Clinical Pharmacists Tend to Reduce Adverse Events


As with the systematic reviews we again focused on studies that attempted to address the relationship between clinical pharmacist activities and improved prescribing and/or a reduction in adverse events. We identified eight new studies not included in the systematic reviews already discussed.

 

Of note, many of the more recent studies have had limited success in overcoming some of those methodological issues seen in some of the older studies. As above, we focused on studies from the United States and other English speaking countries.

 

The studies are summarized in Table 1,

12620131044.jpg







Table 1,
Summary of studies.
A number of the studies contained design flaws that prevented ruling out the contribution of other process modifications or even secular changes to the observed results.

 

Nevertheless, overall, these newer studies continue to support the important roles of clinical pharmacists in reducing prescribing mishaps as well as in improving several patient-level outcomes in various settings.

 

With the exception of one study, studies in which pharmacists participated in a greater number of clinical processes seemed to show stronger effects.


Clinical Pharmacist Interventions Show Little Potential for Harm


Virtually no study has shown an outright potential for harm, apart from an occasional isolated finding such as an ADR rate increase with pharmacist participation on total parenteral nutrition teams (a result that, given its oddity, must remain questionable).

 

27Theoretically speaking, as noted in the original report,4 involvement of clinical pharmacists and implementation of their review processes may result in some delays in dispensing medications.

 

But if these interventions reduce errors (and/or clarify prescribing), this outcome cannot truly be considered a harm, though perhaps it is bothersome and time consuming for patients or providers.


Benefits of Implementation May Outweigh Costs


In terms of resource utilization and costs, the decrease in ADRs that should result from improved prescribing practices should lead to financial savings and/or mitigations in the costs of care.

 

However, information in that regard is limited and generally unclear.

 

Of the two primary studies noted in the 2001 report that estimated annual savings, one based on interventions in an intensive care unit and another based on pharmacist activities in a large university hospital, estimated savings ranged from $270,000 to almost $400,000 per year.

 

4,9,32 Because of differences in outcomes and how they are measured, true costs and/or savings are hard to gauge and, not surprisingly, vary widely.

 

For example, in a review of economic benefits from hospital-based interventions by De Rijdt and colleagus,33financial outcomes, generally stated in estimated annualized savings, ranged anywhere from less than $10,000 to over $500,000, depending on the study and the clinical or interim outcome measured as well as the method of financial evaluation and whether pharmacist costs were included.

 

33 From another perspective, Bond and Raehl28 estimated that the legal settlement costs avoided by the reduction in preventable deaths in the patient population they studied (Medicare) would be nearly $2.4 billion for hospitals that incurred adverse events.

 

While cost or savings estimates depend on a set of assumptions as well as the financial costs of pharmacists' time and effort, these widely varying estimations bring home the point that reduction in medication errors or preventable ADEs can have subsequent “down the line” effects and that financial changes may accrue at a variety of levels depending on the intervention and the seriousness of clinical outcomes (or outcomes avoided).

 

33 A major driver of the cost-effectiveness of a clinical pharmacist intervention is whether new pharmacists need to be hired or if the program can be implemented by reallocation of existing resources and/or the use of lower cost pharmacy technicians for some roles, and thus increase the availability of clinical pharmacists to directly interact with patients and physicians.


Conclusions and Comment


Clinical pharmacists play important roles in a variety of health care settings, and their activities appear to benefit individual patients as well as health care organizations in a multitude of ways, many of which are difficult to isolate when studying whether these interventions objectively lower medication errors or ADEs.

 

Many of the studies are not methodologically strong, and the literature lacks consistency and comparability.

 

Nevertheless, systematic reviews and recent evidence generally supports that pharmacist involvement in intensive care units, particularly when engaging in bedside rounds improves medication management and/or reduces medication errors and preventable ADEs.

 

The existing data for other inpatient and for outpatient care settings are also supportive of a role for pharmacists but less robust than in intensive care units.

 

Data from nursing homes are not as clear as for other settings, but, logically speaking, since medication and prescribing errors occur in this setting, and patients are elderly and more prone to polypharmacy, it is likely by analogy that drug safety in nursing homes will be improved by clinical pharmacist interventions.

 

Similarly, evidence from emergency departments is limited but given the high intensity of care activities and of prescription utilization, it is logical that benefits will accrue from pharmacist interventions.

 

More and better designed studies should help determine the magnitude of the benefit(s), to the extent that such benefits exist, in various health care settings.




References
1.
Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1997 Jan 22-29;277(4):301–6. [PubMed]
2.
Cullen DJ, Bates DW, Small SD, et al. The incident reporting system does not detect adverse drug events: a problem for quality improvement. Jt Comm J Qual Improv. 1995 Oct;21(10):541–8. [PubMed]
3.
Cullen DJ, Sweitzer BJ, Bates DW, et al. Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. Crit Care Med. 1997 Aug;25(8):1289–97. [PubMed]
4.
Kaushal R, Bates DE. Making Health Care Safer: A Critical Analysis of Patient Safety Practices. Evidence Report/Technology Assessment No. 43. Rockville, MD: Agency for Healthcare Research and Quality; Jul, 2001. Chapter 7. The Clinical Pharmacist's Role in Preventing Adverse Events. (Prepared by the University of California at San Francisco–Stanford Evidence-based Practice Center under Contract No. 290-97-0013.) AHRQ Publication No. 01-E058. www.effectivehealthcare.ahrq.gov.
5.
Bates DW, Boyle DL, Vander Vliet MB, et al. Relationship between medication errors and adverse drug events. J Gen Intern Med.1995 Apr;10(4):199–205. [PubMed]
6.
Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995 Jul 5;274(1):29–34. [PubMed]
7.
Jha AK, Kuperman GJ, Teich JM, et al. Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report. J Am Med Inform Assoc. 1998 May-Jun;5(3):305–14. [PMC free article] [PubMed]
8.
Gandhi TK, Burstin HR, Cook EF, et al. Drug complications in outpatients. J Gen Intern Med. 2000 Mar;15(3):149–54. [PMC free article] [PubMed]
9.
Leape LL, Cullen DJ, Clapp MD, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999 Jul 21;282(3):267–70. [PubMed]
10.
Leach RH, Feetam C, Butler D. An evaluation of a ward pharmacy service. J Clin Hosp Pharm. 1981 Sep;6(3):173–82. [PubMed]
11.
Lipton HL, Bero LA, Bird JA, et al. The impact of clinical pharmacists' consultations on physicians' geriatric drug prescribing. A randomized controlled trial. Med Care. 1992 Jul;30(7):646–58. [PubMed]
12.
Ried LD, McKenna DA, Horn JR. Meta-analysis of research on the effect of clinical pharmacokinetics services on therapeutic drug monitoring. Am J Hosp Pharm. 1989 May;46(5):945–51. [PubMed]
13.
Beney J, Bero LA, Bond C. Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes. Cochrane Database Syst Rev. 2000;(3):CD000336. [PubMed]
14.
Hanlon JT, Weinberger M, Samsa GP, et al. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med. 1996 Apr;100(4):428–37. [PubMed]
15.
Kaboli PJ, Hoth AB, McClimon BJ, et al. Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med.2006 May 8;166(9):955–64. [PubMed]
16.
Hanlon JT, Lindblad CI, Gray SL. Can clinical pharmacy services have a positive impact on drug-related problems and health outcomes in community-based older adults? Am J Geriatr Pharmacother. 2004 Mar;2(1):3–13. [PubMed]
17.
Marcum ZA, Handler SM, Wright R, et al. Interventions to improve suboptimal prescribing in nursing homes: A narrative review.Am J Geriatr Pharmacother. 2010 Jun;8(3):183–200. [PMC free article] [PubMed]
18.
Sanghera N, Chan PY, Khaki ZF, et al. Interventions of hospital pharmacists in improving drug therapy in children: a systematic literature review. Drug Saf. 2006;29(11):1031–47. [PubMed]
19.
Cohen V, Jellinek SP, Hatch A, et al. Effect of clinical pharmacists on care in the emergency department: a systematic review.Am J Health Syst Pharm. 2009 Aug 1;66(15):1353–61. [PubMed]
20.
Chedoe I, Molendijk HA, Dittrich ST, et al. Incidence and nature of medication errors in neonatal intensive care with strategies to improve safety: a review of the current literature. Drug Saf. 2007;30(6):503–13. [PubMed]
21.
Kaushal R, Bates DW, Abramson EL, et al. Unit-based clinical pharmacists' prevention of serious medication errors in pediatric inpatients. Am J Health Syst Pharm. 2008 Jul 1;65(13):1254–60. [PubMed]
22.
Wang JK, Herzog NS, Kaushal R, et al. Prevention of pediatric medication errors by hospital pharmacists and the potential benefit of computerized physician order entry. Pediatrics. 2007 Jan;119(1):e77–85. [PubMed]
23.
Rivkin A, Yin H. Evaluation of the role of the critical care pharmacist in identifying and avoiding or minimizing significant drug-drug interactions in medical intensive care patients. J Crit Care. 2011 Feb;26(1):104 e1–6. [PubMed]
24.
LaPointe NM, Jollis JG. Medication errors in hospitalized cardiovascular patients. Arch Intern Med. 2003 Jun 23;163(12):1461–6.[PubMed]
25.
Stoner SC, Worrel JA, Jones MT, et al. Pharmacist-designed and -implemented pharmaceutical care plan for antipsychotic-induced movement disorders. Pharmacotherapy. 2000 May;20(5):583–8. [PubMed]
26.
Simpson JH, Lynch R, Grant J, et al. Reducing medication errors in the neonatal intensive care unit. Arch Dis Child Fetal Neonatal Ed. 2004 Nov;89(6):F480–2. [PMC free article] [PubMed]
27.
Bond CA, Raehl CL. Clinical pharmacy services, pharmacy staffing, and adverse drug reactions in United States hospitals.Pharmacotherapy. 2006 Jun;26(6):735–47. [PubMed]
28.
Bond CA, Raehl CL. Clinical pharmacy services, pharmacy staffing, and hospital mortality rates. Pharmacotherapy. 2007 Apr;27(4):481–93. [PubMed]
29.
Brown JN, Barnes CL, Beasley B, et al. Effect of pharmacists on medication errors in an emergency department. Am J Health Syst Pharm. 2008 Feb 15;65(4):330–3. [PubMed]
30.
Rothschild JM, Churchill W, Erickson A, et al. Medication errors recovered by emergency department pharmacists. Ann Emerg Med. 2010 Jun;55(6):513–21. [PubMed]
31.
Cesarz JL, Steffenhagen AL, Svenson J, et al. Emergency Department Discharge Prescription Interventions by Emergency Medicine Pharmacists. Ann Emerg Med. 2012 May 24 [PubMed]
32.
McMullin ST, Hennenfent JA, Ritchie DJ, et al. A prospective, randomized trial to assess the cost impact of pharmacist-initiated interventions. Arch Intern Med. 1999 Oct 25;159(19):2306–9. [PubMed]
33.
De Rijdt T, Willems L, Simoens S. Economic effects of clinical pharmacy interventions: a literature review. Am J Health Syst Pharm. 2008 Jun 15;65(12):1161–72. [PubMed]
Copyright Notice


 

 

What We Know and Don't Know About Fungal Meningitis Outbreak




Oct. 18, 2012 — In a new perspective piece being published Online First tonight in Annals of Internal Medicine, a physician recalls lessons learned from treating patients affected by the 2002 outbreak of Exophiala (Wangiella) dermatitidis meningitis or arthritis related to contaminated, injectable corticosteroids prepared from a compounding pharmacy.


According to the author, the lessons he learned in 2002 are applicable to the current outbreak.

He warns that compounding of preservative-free corticosteroids requires meticulous sterility to ensure lack of fungal contamination.

Without this sterility, fungus grows aggressively.

As seen with the current cases, once injected, the fungus can travel through the body's tissues rapidly, leading to invasive mycosis.

However, the incubation period from exposure to disease could be up to six months, so exposed patients will need to be followed for a long time.

 

While there were many people exposed to the fungus in 2002, all but one fatal case were successfully treated with voriconazole.


Treatment decisions should be made on a case-by-case basis, but the author writes that evidence from the previous outbreak suggests voriconazole as the logical antifungal drug for initial treatment.

Due to the aggressive and deadly nature of the disease, it is important for physicians to act decisively and early.


The author warns that these outbreaks will happen again if pharmacy societies, the FDA, and the pharmaceutical industry do not work together to regulate pharmacy compounding.


ournal Reference:

1.John R. Perfect. Iatrogenic Fungal Meningitis: Tragedy Repeated. Annals of Internal Medicine, 2012; [link] http://www.sciencedaily.com/releases/2012/09/120906181656.htm
 

 

Genetic Test Will Help Dose Blood Thinner

 

Sep. 6, 2012 — Patients suffering from dangerous blood clots will receive genetic testing to help health professionals at the University of Illinois Hospital & Health Sciences System prescribe the proper dose of the blood-thinner warfarin.

 

The UI Health System is one of the first in the nation to use genetic information to help patients receive the right dose of the drug, which consistently ranks among the leading causes of serious drug-related adverse events.


The genetic test will identify common variants in CYP2C9, an enzyme that breaks down warfarin, and VKORC1, a clotting enzyme that is the target of warfarin, says Larisa Cavallari, UIC associate professor of pharmacy practice and one of the co-directors of the new program.


The ultimate goal, Cavallari said, is to provide personalized medicine to patients, customized to account for their unique genetic ancestry.


"The majority of pharmacogenetic research and use of pharmacogenetics in clinical practice in the United States has been in populations of European descent," says Edith Nutescu, UIC clinical professor of pharmacy practice and co-director of the program.

"We're confident that genotype-guided pharmacotherapy in urban, underserved populations will improve the effectiveness and safety of medications."


Warfarin is difficult to dose, and is usually begun at similar amounts for all patients, Cavallari said.

It It is prescribed to treat deep vein thrombosis and pulmonary embolism and to prevent stroke as a result of atrial fibrillation or heart valve replacement.

It carries a "black-box" warning from the Food and Drug Administration for bleeding risk.


The pharmacogenetics project is a collaboration between the UIC colleges of Pharmacy and of Medicine, including the latter's cardiology, medicine, hematology and clinical pathology departments.

In addition to Cavallari and Nutescu, other directors include Dr. William Galanter, assistant professor of clinical medicine; Carol Dodge, manager of the UI Health Molecular Pathology Laboratory; Dr. Victor Gordeuk, professor of hematology/oncology; Dr. Shrihari Kadkol, associate professor of pathology; and Dr. Thomas Stamos, associate professor of medicine.


Story Source:


The above story is reprinted from materials provided by University of Illinois at Chicago.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.


Web address: http://www.sciencedaily.com/releases/2012/09/ 120906181656.htm

 

Multiple sclerosis

 

اضغط هنا للتحميل    multiple_sclerosis_ms

المزيد من المقالات...

  1. مع الصيدلي الإكلينيكي
Powerd by ZU Elearning Center